June 11, 2026 · Form 4 insider transaction
Kaplan Matthew L. bought 35,000 shares of Nuvectis Pharma, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates.; Includes shares of restricted common stock.